Vol. 24 No. 3 (2020)
ONCOLOGY

Detection of circulating tumour cells in patients with Stage I–III breast cancer

PDF (Русский)
  • V. Ponomarev,
  • O. Chernysheva,
  • S. Polikarpova,
  • E. Bogush,
  • I. Vysotskaya,
  • V. Kirsanov,
  • N. Tupitsyn
V. Ponomarev
Sechenov First Moscow State Medical University, Moscow
Bio
O. Chernysheva
N.N. Blokhin National Medical Research Center of Oncology, Moscow
S. Polikarpova
Sechenov First Moscow State Medical University, Moscow
E. Bogush
Sechenov First Moscow State Medical University, Moscow
I. Vysotskaya
Sechenov First Moscow State Medical University, Moscow
V. Kirsanov
Sechenov First Moscow State Medical University, Moscow
N. Tupitsyn
N.N. Blokhin National Medical Research Center of Oncology, Moscow
DOI: https://doi.org/10.21688/1681-3472-2020-3-107-111

Published 2020-09-30

Keywords

  • breast cancer,
  • circulating tumour cells,
  • liquid biopsy,
  • molecular-biological subtypes of breast cancer

How to Cite

Ponomarev, V., Chernysheva, O., Polikarpova, S., Bogush, E., Vysotskaya, I., Kirsanov, V., & Tupitsyn, N. (2020). Detection of circulating tumour cells in patients with Stage I–III breast cancer. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 24(3), 107–111. https://doi.org/10.21688/1681-3472-2020-3-107-111

Copyright (c) 2020 Ponomarev V.E., Chernysheva O.A., Polikarpova S.B., Bogush E.A., Vysotskaya I.V., Kirsanov V.Yu., Tupitsyn N.N.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Aim. To increase the accuracy of risk stratification of breast cancer Stage I–III patients based on circulating tumour cell (CTC) determination.
Methods. Forty-seven breast cancer patients aged 28–77 years (median, 51 years) who were examined and treated at N.N. Blokhin National Medical Research Center of Oncology between 2015 and 2017 were enrolled in the study. The presence of CTCs was evaluated for all patients before treatment.
Results. CTCs were detected in 85.1% (40 out of 47) of the patients. The CTC detection rate in patients with early and locally-advanced breast cancer was approximately the same, 88.5% (23 of 26) and 81% (17 of 21), respectively (p = 0.7). Another important prognostic factor, which tended to be reliably linked to the frequency of CTC detection, was the grade of malignancy. Grade 2 tumours were more often observed in CTC-positive patients (77.5%) than in CTC-negative patients (22.5%, p = 0.06). None of the remaining clinical and morphological parameters were statistically associated with CTC positivity.
Conclusion. This study demonstrated that regardless of the clinical stage, CTCs were detected with approximately equal frequency in patients with early and locally-advanced breast cancer (88.5% and 81%, respectively). However, owing to the small number of patients studied, none of the differences were found to be statistically significant. Nevertheless, investigations on the relationship between the presence of CTCs, molecular-biological subtypes and grade of malignancy are important to evaluate their use as independent prognostic factors. Further studies are needed to assess the use of CTCs as an additional criterion or prognostic factor in breast cancer management.

Received 17 September 2020. Accepted 25 September 2020.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Author contributions
Conception and design: S.B. Polikarpova, N.N. Tupitsyn, O.A. Chernyshova, V.E. Ponomarev, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov
Data collection: V.E. Ponomarev, O.A. Chernyshova
Data analysis: V.E. Ponomarev, O.A. Chernyshova
Drafting the article: V.E. Ponomarev, O.A. Chernyshova
Critical revision of the article: S.B. Polikarpova, N.N. Tupitsyn, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov
Final approval of the version to be published: V.E. Ponomarev, O.A. Chernysheva, S.B. Polikarpova, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov, N.N. Tupitsyn

PDF (Русский)

References

  1. Shihui M., Ling F., Gui A., Chen S., Sun Y., Li Zh. Predictive value of circulating tumor cells for evaluating short- and long-term efficacy of chemotherapy for breast cancer. Med Sci Mon. 2017;23:4808-4816. PMID: 28986517, PMCID: PMC5642643. https://dx.doi.org/10.12659/msm.903736
  2. Li J., Gregory S.G., Garcia-Blanco M.A., Armstrong A.J. Using circulating tumor cells to inform on prostate cancer biology and clinical utility. Crit Rev Clin Lab Sci. 2015;52(4):191-210. PMID: 26079252. https://dx.doi.org/10.3109/10408363.2015.1023430
  3. Yang C., Zhuang W., Hu Y., Zhu L. Clinical significance of peripheral circulating tumor cell counts in colorectal polyps and non-metastatic colorectal cancer. World J Surg Oncol. 2018;16(1):13. PMID: 29357895, PMCID: PMC5778777. https://dx.doi.org/10.1186/s12957-017-1305-2
  4. Gallo M., De Luca A., Maiello M.R., D'Alessio A., Esposito C., Chicchinelli N., Forgione L., Piccirillo M.C., Rocco G., Morabito A., Botti G., Normanno N. Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. Transl Lung Cancer Res. 2017;6(4):486-498. PMID: 28904891, PMCID: PMC5583074. https://dx.doi.org/10.21037/tlcr.2017.05.07
  5. Neumann M.H., Schneck H., Decker Y., Schömer S., Franken A., Endris V., Pfarr N., Weichert W., Niederacher D., Fehm T., Neubauer H. Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch® system and the CellCelector™. Biotechnol Prog. 2017;33(1):125-132. PMID: 27126369. https://dx.doi.org/10.1002/btpr.2294
  6. Krishnamurthy S. The emerging role of circulating tumor cells in breast cancer. Cancer Cytopathol. 2012;120(3):161-166. PMID: 22275137. https://dx.doi.org/10.1002/cncy.20207
  7. Bidard F.C., Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., Marty M., Pierga J.-Y. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 2010;21(4):729-733. PMID: 19850639. https://dx.doi.org/10.1093/annonc/mdp391
  8. Kang Y., Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013;23(5):573-581. PMID: 23680145, PMCID: PMC3667710. doi: https://dx.doi.org/10.1016/j.ccr.2013.04.017
  9. Banys-Paluchowski M., Schneck H., Blassl C., Schultz S., Meier-Stiegen F., Niederacher D., Krawczyk N., Ruckhaeberle E., Fehm T., Neubauer H. Prognostic relevance of circulating tumor cells in molecular subtypes of breast cancer. Geburtshilfe Frauenheilkd. 2015;75(3):232-237. https://dx.doi.org/10.1055/s-0035-1545788
  10. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793-802. https://dx.doi.org/10.1056/NEJMoa050434
  11. Alix-Panabieres C., Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479-491. PMID: 26969689. https://dx.doi.org/10.1158/2159-8290.CD-15-1483
  12. Joosse S.A., Gorges T.M., Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014;7(1):1-11. PMID: 25398926, PMCID: PMC4309663. https://dx.doi.org/10.15252/emmm.201303698
  13. Pantel K., Alix-Panabieres C. Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Res. 2013;73(21):6384-6388. PMID: 24145355. https://dx.doi.org/10.1158/0008-5472.CAN-13-2030
  14. Maltoni R., Gallerani G., Fici P., Rocca A., Fabbri F. CTCs in early breast cancer: A path worth taking. Cancer Lett. 2016;376(2):205-210. PMID: 27060205. https://dx.doi.org/10.1016/j.canlet.2016.03.051